Clinical Trials Logo

Prostatic Hyperplasia clinical trials

View clinical trials related to Prostatic Hyperplasia.

Filter by:

NCT ID: NCT00461123 Completed - Clinical trials for Prostatic Hypertrophy, Benign

Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy

Start date: March 2007
Phase: Phase 2
Study type: Interventional

The greenlight laser has an absorption maximum which is exactly the same as for hemoglobin. In the presence of hemoglobin, its application causes vaporization of the tissue and this effect depends on the concentration of hemoglobin in the respective tissue. Therefore, increase of blood-flow in the tissue (here: prostate gland) should exert better efficacy of the laser application and consequently shortening of the required duration of laser application.

NCT ID: NCT00457457 Completed - Clinical trials for Prostatic Hyperplasia

Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.

Start date: May 2007
Phase: Phase 2
Study type: Interventional

This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate. Patients will complete a series of questionnaires before, during and after treatment to assess if UK-369,003 has improved their urinary symptoms and erectile function . There will be several blood samples taken during the study to asses the level of drug in the blood and correlate it with the responses to the questionnaires.

NCT ID: NCT00451191 Completed - Clinical trials for Benign Prostatic Hyperplasia

Botulinum Toxin Injection for the Management of BPH

MIST2
Start date: October 2006
Phase: Phase 2
Study type: Interventional

This is a double-blind randomized phase II trial to determine whether two different doses of BoNT/A injection into the prostate gland demonstrate sufficient improvement in the management of lower urinary symptoms due to BPH to warrant more extensive research. Subjects will receive either a 100U or 300U dose. Participation will last 1 year.

NCT ID: NCT00427882 Completed - Clinical trials for Prostatic Hyperplasia

Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study

Start date: September 2006
Phase: Phase 4
Study type: Interventional

Primary: To assess improvement in ejaculation from baseline to the end of treatment (Week 12 or premature withdrawal) with Alfuzosin 10mg OD, using MSHQ score. Secondary: - To evaluate sexual function improvement - To evaluate LUTS (Lower Uninary Tract Symptoms) improvement - To evaluate the association between LUTS severity and sexual function. - To assess the safety and the tolerability of Alfuzosin 10mg OD.

NCT ID: NCT00427817 Completed - Adenoma, Prostatic Clinical Trials

PRO-STATE:Search for a Protein Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins in Prostate Carcinoma

Start date: August 2006
Phase: N/A
Study type: Observational

The main objective of this study is to realise serum protein profiles for each patient undergoing a prostate biopsy and to identify relevant proteins.

NCT ID: NCT00427219 Completed - Clinical trials for Benign Prostatic Hypertrophy

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

Start date: January 23, 2007
Phase: Phase 2
Study type: Interventional

This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.

NCT ID: NCT00416390 Completed - Prostate Cancer Clinical Trials

Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia

Start date: n/a
Phase: N/A
Study type: Interventional

RATIONALE: Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. Eating a diet high in lycopene, a substance found in tomatoes and tomato products, may keep cancer from forming or growing. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This randomized clinical trial is studying how well lycopene works in treating patients with prostate cancer or benign prostatic hyperplasia.

NCT ID: NCT00409357 Completed - Clinical trials for Benign Prostatic Hyperplasia

Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia

Start date: November 2004
Phase: Phase 2
Study type: Interventional

The primary objective is to assess the dose-response relationship of SL77.0499 10 (alfuzosin hydrochloride) 5 mg, 10 mg, 15 mg, and placebo once daily during a 12-week oral administration period for the efficacy in patients with lower urinary tract symptoms (LUTS) related to BPH. Secondary objectives are to assess the efficacy of each dose of alfuzosin as compared with placebo and to assess the safety of each dose of alfuzosin.

NCT ID: NCT00408954 Completed - Clinical trials for Prostatic Hyperplasia

Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms

Start date: March 2007
Phase: Phase 2
Study type: Interventional

This is a pilot study to generate hypotheses about the urodynamic effects of UK-369,003 in men with lower urinary tract symptoms.

NCT ID: NCT00407329 Completed - BPH Clinical Trials

Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia

Start date: November 2006
Phase: N/A
Study type: Observational

We hypothesize that the absolute or relative serum or urine levels of the urokinase plasminogen activator system, including uPA, uPAR and PAI-1,2 (inhibitors of the uPAR/uPA complex), are associated with inflammation in prostatic tissue.